Join Criterion Edge’s VP of Scientific and Medical Affairs, Kyoko Hattori for an informational webinar on Endpoint Adjudication by the Clinical Endpoints Committee.
Date/Time: September 12th, 2018 at 11 AM PST/2 PM EST
Kyoko brings over 30 years of expertise to share with clinical field scientists and managers, drug safety specialists, medical monitors, and more. Join Kyoko and other senior professionals during the webinar to learn more about familiarization and guidance using endpoint adjudication by the CEC. (more…)
There is no doubt that establishing state of the art is a challenge. It ranges from key information on the medical condition to a neutral, comprehensive analysis of treatment options, and culminates in a succinct yet comprehensive presentation that defines the currently accepted safety and performance standards against which the device is measured. Not surprisingly, common pitfalls include a perspective that is too broad and inclusion of too much detail, or a perspective that is too narrow, omitting relevant indications and alternative therapeutic options. An important critical aspect of the clinical evaluation that relies on state of the art data is also to appropriately define the position of the device within the currently available treatment portfolio.
The large number of mentions of state of the art throughout MEDDEV 2.7/1 rev 4 provide not only a comprehensive description of the importance, purpose, and role of establishing the state of the art, but also inform on how to incorporate this analysis into the clinical evaluation. The image below summarizes several core roles of this analysis.
Prior to MEDDEV 2.7/1 rev 4, guidance referred to state of the art only vaguely. MEDDEV 2.7/1 rev 3 requested the discussion of clinical data “in comparison with” and “taking account of” state of the art, and that the clinical literature data cited “reflect current medical practice and the generally acknowledged state of the art technologies”. From a methodological standpoint, this is not much guidance. Thus, methodology, depth, and presentation of the medical background for a device was largely left to one’s interpretation, and thus conducted inconsistently, or, at least, heterogeneously. (more…)
As business increases, medical device and pharmaceutical companies are finding success turning to outside vendors to meet their technical and regulatory writing needs. In doing so, these organizations gain real and specific benefits that, because of a streamlined approach, can lead to a bigger bottom line. Below are a few examples of the advantages that your company can gain by outsourcing your writing needs.
June 17-21, 2019
Crowne Plaza Brussels – Le Palace, Brussels
Don’t miss out on the early bird discount – register before March 29th to get £300 off.
Save an additional 25% off your registration fee by clicking this link.
Already registered? We’ll see you there! Book at meeting with us at booth #9.